JP2019507177A5 - - Google Patents

Download PDF

Info

Publication number
JP2019507177A5
JP2019507177A5 JP2018546518A JP2018546518A JP2019507177A5 JP 2019507177 A5 JP2019507177 A5 JP 2019507177A5 JP 2018546518 A JP2018546518 A JP 2018546518A JP 2018546518 A JP2018546518 A JP 2018546518A JP 2019507177 A5 JP2019507177 A5 JP 2019507177A5
Authority
JP
Japan
Prior art keywords
oxo
pyrrolidine
carbonitrile
dihydro
spiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018546518A
Other languages
English (en)
Japanese (ja)
Other versions
JP6959247B2 (ja
JP2019507177A (ja
Filing date
Publication date
Priority claimed from GBGB1603779.8A external-priority patent/GB201603779D0/en
Application filed filed Critical
Publication of JP2019507177A publication Critical patent/JP2019507177A/ja
Publication of JP2019507177A5 publication Critical patent/JP2019507177A5/ja
Priority to JP2021158986A priority Critical patent/JP7280928B2/ja
Application granted granted Critical
Publication of JP6959247B2 publication Critical patent/JP6959247B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018546518A 2016-03-04 2017-03-02 脱ユビキチン化酵素(dub)阻害剤としてのスピロ縮合ピロリジン誘導体 Active JP6959247B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021158986A JP7280928B2 (ja) 2016-03-04 2021-09-29 脱ユビキチン化酵素(dub)阻害剤としてのスピロ縮合ピロリジン誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1603779.8 2016-03-04
GBGB1603779.8A GB201603779D0 (en) 2016-03-04 2016-03-04 Novel compounds
PCT/GB2017/050565 WO2017149313A1 (en) 2016-03-04 2017-03-02 Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021158986A Division JP7280928B2 (ja) 2016-03-04 2021-09-29 脱ユビキチン化酵素(dub)阻害剤としてのスピロ縮合ピロリジン誘導体

Publications (3)

Publication Number Publication Date
JP2019507177A JP2019507177A (ja) 2019-03-14
JP2019507177A5 true JP2019507177A5 (cg-RX-API-DMAC7.html) 2020-02-27
JP6959247B2 JP6959247B2 (ja) 2021-11-02

Family

ID=55859019

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018546518A Active JP6959247B2 (ja) 2016-03-04 2017-03-02 脱ユビキチン化酵素(dub)阻害剤としてのスピロ縮合ピロリジン誘導体
JP2021158986A Active JP7280928B2 (ja) 2016-03-04 2021-09-29 脱ユビキチン化酵素(dub)阻害剤としてのスピロ縮合ピロリジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021158986A Active JP7280928B2 (ja) 2016-03-04 2021-09-29 脱ユビキチン化酵素(dub)阻害剤としてのスピロ縮合ピロリジン誘導体

Country Status (19)

Country Link
US (3) US10654853B2 (cg-RX-API-DMAC7.html)
EP (2) EP4067355A1 (cg-RX-API-DMAC7.html)
JP (2) JP6959247B2 (cg-RX-API-DMAC7.html)
KR (1) KR102384139B1 (cg-RX-API-DMAC7.html)
CN (1) CN108602823B (cg-RX-API-DMAC7.html)
AU (1) AU2017225371B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018017086B1 (cg-RX-API-DMAC7.html)
CA (1) CA3016370C (cg-RX-API-DMAC7.html)
CO (1) CO2018009275A2 (cg-RX-API-DMAC7.html)
ES (1) ES2919549T3 (cg-RX-API-DMAC7.html)
GB (1) GB201603779D0 (cg-RX-API-DMAC7.html)
IL (1) IL261552B (cg-RX-API-DMAC7.html)
MA (1) MA43701A (cg-RX-API-DMAC7.html)
MX (1) MX382562B (cg-RX-API-DMAC7.html)
MY (1) MY196836A (cg-RX-API-DMAC7.html)
RU (1) RU2730552C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201807301SA (cg-RX-API-DMAC7.html)
WO (1) WO2017149313A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201803910B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3277677T (lt) 2015-03-30 2021-05-25 Mission Therapeutics Limited 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai
EP3322702B1 (en) 2015-07-14 2019-11-20 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) * 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
MA43753A (fr) 2016-03-24 2018-11-28 Mission Therapeutics Ltd Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
ES2850349T3 (es) 2016-09-27 2021-08-27 Mission Therapeutics Ltd Derivados de cianopirrolidina con actividad como inhibidores de USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
JP7208931B2 (ja) 2017-06-20 2023-01-19 ミッション セラピューティクス リミティド Dub阻害剤としての活性をもつ置換シアノピロリジン類
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors
EP3837262B1 (en) 2018-08-14 2026-06-17 Amgen Inc. N-cyano-7-azanorbornane derivatives and uses thereof
EP4218934B1 (en) 2018-10-05 2025-06-18 Forma Therapeutics, Inc. Inhibiting ubiquitin-specific protease 30 (usp30)
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
MX2022012578A (es) 2020-04-08 2022-11-07 Mission Therapeutics Ltd N-cianopirrolidinas con actividad como inhibidores de usp30.
KR20230016674A (ko) 2020-05-28 2023-02-02 미션 테라퓨틱스 엘티디 미토콘드리아 기능장애의 치료를 위한 usp30 억제제로서 n-(1-시아노피롤리딘-3-일)-5-(3-(트라이플루오로메틸)페닐)옥사졸-2-카복스아미드 유도체 및 상응하는 옥사다이아졸 유도체
WO2021245186A1 (en) 2020-06-04 2021-12-09 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
RS67140B1 (sr) 2020-06-08 2025-09-30 Mission Therapeutics Ltd 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primenu u lečenju mitohondrijske disfunkcije, kancera i fibroze
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
CN116143782B (zh) * 2021-11-22 2024-04-12 西南大学 一类螺[吡咯烷-2,3'-喹啉]-2'-酮类衍生物的设计合成与应用
WO2023099561A1 (en) 2021-12-01 2023-06-08 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
JP2025500506A (ja) * 2021-12-23 2025-01-09 ザ・カトリック・ユニヴェルシテイト・ルーバン Yap/taz-teadを阻害するためのスピロ及び関連類似体
WO2024151847A1 (en) * 2023-01-13 2024-07-18 The University Of North Carolina At Chapel Hill Identification of otud7b inhibitor 7bi and its application in reducing growth of nsclc and leukemia cells
GB202408928D0 (en) 2024-06-21 2024-08-07 Mission Therapeutics Ltd Novel compounds
GB202411060D0 (en) 2024-07-29 2024-09-11 Mission Therapeutics Ltd Novel compounds
GB202500610D0 (en) 2025-01-16 2025-03-05 Mission Therapeutics Ltd Novel compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530384A (ja) 2000-04-06 2003-10-14 メルク フロスト カナダ アンド カンパニー カテプシンシステインプロテアーゼ阻害薬
US7759383B2 (en) 2005-02-22 2010-07-20 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
CA2661354C (en) * 2006-08-30 2012-12-18 The Regents Of The University Of Michigan New small molecule inhibitors of mdm2 and the uses thereof
WO2008144507A2 (en) 2007-05-16 2008-11-27 President And Fellows Of Harvard College Spirooxindole inhibitors of aurora kinase
US20090264431A1 (en) * 2007-08-20 2009-10-22 Palovich Michael R Novel cathepsin c inhibitors and their use
US8088815B2 (en) * 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
GB0922589D0 (en) 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
TR201807311T4 (tr) * 2011-03-10 2018-06-21 Daiichi Sankyo Co Ltd Dispiropirolidin derivesi.
EP2752191A1 (en) 2013-01-07 2014-07-09 Sanofi Compositions and methods using hdm2 antagonist and mek inhibitor
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
LT3277677T (lt) 2015-03-30 2021-05-25 Mission Therapeutics Limited 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai
EP3322702B1 (en) 2015-07-14 2019-11-20 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) * 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
MA43753A (fr) 2016-03-24 2018-11-28 Mission Therapeutics Ltd Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
ES2850349T3 (es) 2016-09-27 2021-08-27 Mission Therapeutics Ltd Derivados de cianopirrolidina con actividad como inhibidores de USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物

Similar Documents

Publication Publication Date Title
TWI766261B (zh) 蛋白質酪胺酸磷酸酶抑制劑
ES2870203T3 (es) Compuesto derivado tricíclico, método para prepararlo y composición farmacéutica que comprende el mismo
JP2024514338A (ja) 複素環式誘導体阻害剤及びその調製方法及びその用途
US9926271B2 (en) Octahydrocyclopentapyrroles, their preparation and use
Da Silva et al. Biological activity and synthetic metodologies for the preparation of fluoroquinolones, a class of potent antibacterial agents
JP2019532945A5 (cg-RX-API-DMAC7.html)
US10787453B2 (en) Octahydropyrrolopyrroles their preparation and use
US20250236612A1 (en) Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
JP2019509274A5 (cg-RX-API-DMAC7.html)
CN111484480A (zh) 一种多环类衍生物抑制剂、其制备方法和应用
CN109562113A (zh) 用于靶蛋白降解的螺环降解决定子体
KR20170016493A (ko) 치환된 다이하이드로이소퀴놀린온 화합물
JP2018524367A5 (cg-RX-API-DMAC7.html)
RU2018133279A (ru) Спироконденсированные пирролидиновые производные в качестве ингибиторов деубиквитилирующих ферментов (DUB)
JP2018502930A (ja) TrkAキナーゼの阻害剤
PT2794600T (pt) Derivados de 2,3-di-hidro-benzo[1,4]oxazina e compostos relacionados como inibidores de fosfoinositídeo-3-cinase (pi3k) para o tratamento de, por exemplo, artrite reumatoide
CN105518001A (zh) Bet蛋白抑制性的改性的二氢喹喔啉酮类化合物和二氢吡啶并吡嗪酮类化合物
TWI818424B (zh) 含氮多環稠環類化合物,其藥物組合物、製備方法和用途
CN108699065A (zh) 作为激酶抑制剂的三环类化合物和组合物
WO2000032192A1 (en) Drugs
CN104447701A (zh) 吡唑类衍生物及其用途
WO1997017970A1 (fr) Inhibiteurs de la neurotoxicite de l'acide kainique et derives de la pyridothiazine
TWI838644B (zh) 芳甲醯取代的三環化合物及其製法和用途
RU2799449C2 (ru) Ингибиторы протеинтирозинфосфатазы
CN117460731A (zh) 杂环内酰胺类化合物,其制法与医药上的用途